CDK12 and prostate cancer: In contrast, analysis of circulating tumor DNA obtained from 35 Japanese patients with advanced‐stage prostate cancer revealed frequent alterations in the homologous recombination deficiency pathway, including BRCA2 mutations identified in 11% of patients, ATM mutations in 9%, and CDK12 mutations in 9%.18